Literature DB >> 23394882

Does suspicion of prostate cancer on integrated T2 and diffusion-weighted MRI predict more adverse pathology on radical prostatectomy?

Michael S Borofsky1, Andrew B Rosenkrantz, Nitya Abraham, Rajat Jain, Samir S Taneja.   

Abstract

OBJECTIVE: To determine whether suspicion for tumor on prostate MRI incorporating T2-weighted imaging (T2-WI) and diffusion-weighted imaging (DWI) predicts more adverse pathology on radical prostatectomy (RP).
METHODS: From 2007 to 2009, 154 patients underwent 1.5 Tesla pelvic-phased-array magnetic resonance imaging (MRI) of the prostate that included T2-WI and DWI before RP. MRI examinations were retrospectively reviewed and grouped by degree of suspicion for tumor: no suspicion for tumor (NST, n = 15), equivocal suspicion for tumor (EST, n = 60), or strong suspicion for tumor (SST, n = 79). The NST/EST groups were combined and compared to the SST group. Preoperative variables were used to assemble a multivariate model. Outcomes reflective of adverse pathology included primary Gleason grade ≥4, pathologic stage ≥T3 (≥pT3), and tumor upgrading. Subgroup analysis was performed for patients meeting eligibility criteria for active surveillance (n = 55). For this analysis, the NST group was compared to the EST/SST groups.
RESULTS: SST status was associated with adverse preoperative risk factors for aggressive disease. Univariate analysis demonstrated significant association between SST and primary Gleason ≥4 pathology and stage ≥pT3 (P <.05). On multivariate analysis, SST was independently predictive of primary Gleason ≥4 pathology (odds ratio [OR] 6.14, 95% confidence interval [CI] 1.97-19.2) and Gleason upgrading (OR 2.47, 95% CI 1.01-6.02). Among patients eligible for active surveillance, those in the NST group had decreased likelihood of Gleason ≥7 disease or stage ≥pT3 compared to the EST/SST groups (7.7% vs 47.6%, P = .01).
CONCLUSION: Increased tumor suspicion on T2-WI/DWI MRI is indicative of adverse pathology on RP. These findings suggest a role for MRI in pretreatment risk assessment.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23394882     DOI: 10.1016/j.urology.2012.12.026

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer.

Authors:  Tatsuo Gondo; Hedvig Hricak; Evis Sala; Junting Zheng; Chaya S Moskowitz; Melanie Bernstein; James A Eastham; Hebert Alberto Vargas
Journal:  Eur Radiol       Date:  2014-08-07       Impact factor: 5.315

2.  The role of MRI-targeted and confirmatory biopsies for cancer upstaging at selection in patients considered for active surveillance for clinically low-risk prostate cancer.

Authors:  François Marliere; Philippe Puech; Ahmed Benkirane; Arnauld Villers; Laurent Lemaitre; Xavier Leroy; Nacim Betrouni; Adil Ouzzane
Journal:  World J Urol       Date:  2014-05-12       Impact factor: 4.226

3.  Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance.

Authors:  Robert R Flavell; Antonio C Westphalen; Carmin Liang; Christopher C Sotto; Susan M Noworolski; Daniel B Vigneron; Zhen J Wang; John Kurhanewicz
Journal:  Abdom Imaging       Date:  2014-10

Review 4.  Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancer.

Authors:  Seyed Saeid Dianat; H Ballentine Carter; Katarzyna J Macura
Journal:  Urol Oncol       Date:  2013-06-17       Impact factor: 3.498

5.  Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists.

Authors:  Michela Antonelli; Edward W Johnston; Nikolaos Dikaios; King K Cheung; Harbir S Sidhu; Mrishta B Appayya; Francesco Giganti; Lucy A M Simmons; Alex Freeman; Clare Allen; Hashim U Ahmed; David Atkinson; Sebastien Ourselin; Shonit Punwani
Journal:  Eur Radiol       Date:  2019-06-11       Impact factor: 5.315

6.  MRI grading for the prediction of prostate cancer aggressiveness.

Authors:  M Boschheidgen; L Schimmöller; C Arsov; F Ziayee; J Morawitz; B Valentin; K L Radke; M Giessing; I Esposito; P Albers; G Antoch; T Ullrich
Journal:  Eur Radiol       Date:  2021-11-08       Impact factor: 7.034

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.